Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.71 USD | -1.16% | -5.00% | -88.38% |
Business Summary
Number of employees: 384
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Relyvrio (Sodium Phenylbutyrate and Taurursodiol)
100.0
%
| 22 | 100.0 % | 381 | 100.0 % | +1,612.94% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 22 | 100.0 % | 381 | 100.0 % | +1,612.94% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Justin Klee
FOU | Founder | 33 | 12-12-31 |
Josh Cohen
FOU | Founder | 32 | 12-12-31 |
Jim Frates
DFI | Director of Finance/CFO | 56 | 20-12-31 |
Chief Tech/Sci/R&D Officer | 71 | Nov. 27 | |
Lindsey Allen
IRC | Investor Relations Contact | - | - |
Gina Mazzariello
LAW | General Counsel | 52 | 22-02-22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
George Milne
CHM | Chairman | 80 | 14-12-31 |
Kari Firestone
BRD | Director/Board Member | 68 | 23-03-15 |
Paul R. Fonteyne
BRD | Director/Board Member | 62 | 21-03-28 |
Daphne Quimi
BRD | Director/Board Member | 58 | 21-06-28 |
Josh Cohen
FOU | Founder | 32 | 12-12-31 |
Justin Klee
FOU | Founder | 33 | 12-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 68,005,749 | 58,032,930 ( 85.34 %) | 0 | 85.34 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-88.38% | 118M | |
-2.30% | 90.28B | |
-1.97% | 39.5B | |
-15.47% | 31.71B | |
+61.28% | 26.41B | |
-22.81% | 14.34B | |
-8.82% | 12.89B | |
-11.77% | 11.8B | |
-45.97% | 10.95B | |
+3.30% | 8.85B |
- Stock Market
- Equities
- AMLX Stock
- Company Amylyx Pharmaceuticals, Inc.